2 completed, 2 recruiting. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Recruiting 2 |
| Phase 1 | 1 | Completed 1 |
Follow Azenosertib: new trials by email Literature Review of Azenosertib trials Research Report on Azenosertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Azenosertib in Uterine Serous Carcinoma: Biomarker Study Azenosertib - Uterine Serous Carcinoma, Uterine Carcinoma | Phase 2 | Recruiting | Joyce Liu, MD | 25 | 2025-03-05 | 2026-03-02 |
| A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer azenosertib - High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Phase 2 | Recruiting | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 310 | 2022-02-17 | 2026-10-30 |
| A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer Azenosertib, Niraparib - Ovarian Cancer, Platinum-resistant Ovarian Cancer | Phase 1 / Phase 2 | Completed | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 117 | 2022-01-27 | 2026-03-18 |
| A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma Azenosertib - Uterine Serous Carcinoma | Phase 2 | Completed | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 92 | 2021-07-28 | 2026-03-18 |
Ovarian Neoplasms (2) · Cystadenocarcinoma, Serous (1) · Fallopian Tube Neoplasms (1) · Uterine Neoplasms (1)
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc (3) · Joyce Liu, MD (1)
United States (4) · Australia (2) · France (2) · Belgium (1) · Canada (1) · Georgia (1) · Italy (1) · Poland (1) · Puerto Rico (1) · South Korea (1) · Spain (1)